Veriskin, Inc. has initiated a 100+ human clinical study to test the TruScore device. The IRB approved study is conducted by Palo Alto Medical Foundation (a division of Sutter Health).
Veriskin Invited to Present at TedX San Diego Innovation Alley
Veriskin, Inc. was invited to present at TedXs' Innovation Alley held in downtown San Diego that showecased 20 of San Diego’s most innovative companies and entrepreneurs. See event photos here.
Veriskin Receives NIH Grant to Pursue Skin Cancer Screening Technology
Veriskin, Inc. has been awarded s $1.875M grant by the National Institutes of Health to develop a novel technology for non-invasive skin cancer screening. The National Cancer Institute that issued the award cited “the exceptionally high impact that the proposed device is expected to make in the field of non-invasive skin cancer diagnostics”.